[{"address1": "180 North LaSalle Street", "address2": "Suite 1600", "city": "Chicago", "state": "IL", "zip": "60601", "country": "United States", "phone": "844 445 5704", "website": "https://www.xerispharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.", "fullTimeEmployees": 377, "companyOfficers": [{"maxAge": 1, "name": "Mr. John P. Shannon", "age": 62, "title": "CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 918153, "exercisedValue": 0, "unexercisedValue": 148377}, {"maxAge": 1, "name": "Mr. Steven M. Pieper", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 681142, "exercisedValue": 0, "unexercisedValue": 15586}, {"maxAge": 1, "name": "Ms. Beth P. Hecht J.D.", "age": 60, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 695443, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul R. Edick J.D.", "age": 68, "title": "Senior Advisor", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 1206766, "exercisedValue": 0, "unexercisedValue": 590310}, {"maxAge": 1, "name": "Dr. Kenneth E. Johnson Pharm. D., Pharm.D.", "age": 61, "title": "Senior VP of Global Development & Medical Affairs", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 596967, "exercisedValue": 0, "unexercisedValue": 31173}, {"maxAge": 1, "name": "Ms. Allison  Wey", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Conner", "title": "SVP of Quality and Chief Compliance & Risk Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kendal  Korte", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  McCulloch", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.36, "open": 3.37, "dayLow": 3.27, "dayHigh": 3.59, "regularMarketPreviousClose": 3.36, "regularMarketOpen": 3.37, "regularMarketDayLow": 3.27, "regularMarketDayHigh": 3.59, "beta": 1.285, "forwardPE": -16.190477, "volume": 2979308, "regularMarketVolume": 2979308, "averageVolume": 1609073, "averageVolume10days": 1205490, "averageDailyVolume10Day": 1205490, "bid": 3.38, "ask": 3.41, "bidSize": 400, "askSize": 400, "marketCap": 506875392, "fiftyTwoWeekLow": 1.69, "fiftyTwoWeekHigh": 3.87, "priceToSalesTrailing12Months": 2.705341, "fiftyDayAverage": 3.3284, "twoHundredDayAverage": 2.6146, "currency": "USD", "enterpriseValue": 708439936, "profitMargins": -0.33685002, "floatShares": 142499514, "sharesOutstanding": 149080992, "sharesShort": 9517445, "sharesShortPriorMonth": 10146898, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.0638, "heldPercentInsiders": 0.03921, "heldPercentInstitutions": 0.4396, "shortRatio": 5.53, "shortPercentOfFloat": 0.0654, "impliedSharesOutstanding": 149080992, "bookValue": -0.19, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -63113000, "trailingEps": -0.43, "forwardEps": -0.22, "enterpriseToRevenue": 3.781, "enterpriseToEbitda": -21.427, "52WeekChange": 0.26792455, "SandP52WeekChange": 0.24176979, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "XERS", "underlyingSymbol": "XERS", "shortName": "Xeris Biopharma Holdings, Inc.", "longName": "Xeris Biopharma Holdings, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "8f5f7125-cc84-3c21-a68b-9d3090e24887", "messageBoardId": "finmb_105901792", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.4, "targetHighPrice": 6.6, "targetLowPrice": 3.0, "targetMeanPrice": 4.76667, "targetMedianPrice": 5.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 69402000, "totalCashPerShare": 0.466, "ebitda": -33063000, "totalDebt": 270964992, "quickRatio": 1.215, "currentRatio": 1.789, "totalRevenue": 187360992, "revenuePerShare": 1.301, "returnOnAssets": -0.08701, "grossProfits": 152436992, "freeCashflow": -30717750, "operatingCashflow": -31485000, "revenueGrowth": 0.123, "grossMargins": 0.8136, "ebitdaMargins": -0.17647, "operatingMargins": -0.23758, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]